Table 3 Ten signaling agents and their targets with dissociation constant
From: A microRNA molecular modeling extension for prediction of colorectal cancer treatment
Drug | Target | Dissociation constant (nM) |
|---|---|---|
Dasatinib | ABL1 | 0.53 |
| Â | EPHA3 | 0.09 |
| Â | EPHA5/8 | 0.24 |
| Â | PDGFRA | 0.47 |
| Â | LYN | 0.57 |
| Â | KIT | 0.62 |
| Â | SRC | 0.21 |
Erlotinib | EGFR | 0.67 |
| Â | ERBB4 | 230 |
| Â | LYN | 530 |
| Â | SRC | 700 |
Everolimus | MTOR | 2.2 |
Gefitinib | EGFR | 1.0 |
| Â | ERBB2 | 3500 |
| Â | ERBB4 | 410 |
| Â | LYN | 990 |
Imatinib | ABL1 | 12.0 |
| Â | ABL2 | 10.0 |
| Â | KIT | 14.0 |
| Â | PDGFRA | 31.0 |
| Â | PDGFRB | 14.0 |
Lapatinib | EGFR | 2.4 |
| Â | ERBB2 | 7.0 |
| Â | ERBB4 | 54.0 |
Nilotinib | KIT | 22 |
| Â | PDGFRB | 22 |
Sorafenib | DDR1 | 1.5 |
| Â | DDR2 | 6.6 |
Sunitinib | FLT3 | 0.47 |
| Â | KIT | 0.37 |
| Â | PDGFRA | 0.79 |
| Â | PDGFRB | 0.08 |
Temsirolimus | MTOR | 2.2 |
| Â | VEGFR | 0.75 |